When was In Silico founded?

In Silico was founded in 2014 and raised its 1st funding round within a year of its incorporation.

Where is In Silico located?

In Silico is headquartered in Cambridge, United States.

Who is the current CEO of In Silico?

Alex Zhavoronkov and Feng Ren s of In Silico. Alex Zhavoronkov has also founded 1 company and is an angel investors in 1 startup.

How many employees does In Silico have?

As of Jun 30, 2026, the latest employee count at In Silico is 284.

Is In Silico a funded company?

In Silico is a funded company, having raised a total of $510M across 12 funding rounds to date. The company's 1st funding round was a $195K Grant (prize money) round, raised on Apr 01, 2014.

When was the latest funding round of In Silico?

In Silico's latest funding was a $110M Series E round on Jan 07, 2025, with participation from 2 investors. Its primary sector is Life Sciences Tech. In United States, the Life Sciences Tech sector has seen $2.61B in funding in 2026 to date.

What is the annual revenue of In Silico?

Annual revenue of In Silico is between $1 and $1M as on Jul 18, 2017

Is In Silico a Life Sciences Tech company?

The primary sectors of In Silico are Life Sciences Tech, Generative AI and Artificial Intelligence.

Where does In Silico rank among its competitors?

In Silico ranks 8th amongst 192 active competitors, of which 70 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Isomorphic Labs, which secured $2.1B in May, 2026.

Who are the top competitors of In Silico?

In Silico's top competitors include Schrodinger, Recursion Pharmaceuticals and XtalPi. Among them, Isomorphic Labs secured the most recent funding round in May, 2026.

In Silico - 2026 Company Profile, Team, Funding & Competitors

Sectors and market segments that In Silico operate in

In Silico serves in the HealthTech, Life Sciences, High Tech, Native AI market segments.The primary business model of In Silico are:

Company Details

AI-enabled bioinformatics platform for drug discovery and biomarker development. The company provides solutions and services such as custom drug discovery engines, biomarker discovery, and aging research tools to academia, pharmaceutical, and cosmetics companies. Also, it has developed a product PHARMA.AI which includes modules for drug discovery such as PandaOmics, Chemistry42, and InClinico.

Website: insilico.com
Email ID: *****@insilico.com

Key Metrics

Founded Year

2014

Location

Cambridge, United States

Stage

Public

Total Funding

$510M in 12 rounds

Latest Funding Round

Series E, Jan 07, 2025, $110M

Investors

Qiming Venture Partners & 37 more

Ranked

8^th among 192 active competitors

Annual Revenue

$1 - $1M as on Jul 18, 2017

Employee Count

284 as on Jun 30, 2026

Similar Companies

OpenEvidence & 2520 more

Exit Details

Public

View In Silico's full profile

In Silico is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Insilico Medicine, Inc. CIN: 1698493 , United States, Active		$1 - $1M (As on Jul 18, 2017)	-	-

In Silico got listed on Dec 30, 2025.

Click here to take a look at In Silico's IPO in detail

In Silico has raised a total funding of $510M over 12 rounds. Its first funding round was on Apr 01, 2014. Its latest funding round was a Series E round on Jan 07, 2025 for $110M. 2 investors participated in its latest round. In Silico has 37 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of In Silico:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 07, 2025	$110M	Series E	$1B	-	Value Partners, Pudong Venture Capital	-
Aug 11, 2022	$35M	Series D	-	-	Prosperity7 Ventures	-
Jun 07, 2022	$60M	Series D	$1B	-	Qiming Venture Partners	BHR, Warburg Pincus, Bold Capital Partners, Pavilion Capital Partners, LanTing Capital, B Capital

Access funding benchmarks and valuations. Sign up today!

View details of In Silico's funding rounds and investors

The founders of In Silico are Alex Zhavoronkov and Stephanie Williams. Alex Zhavoronkov and Feng Ren are the CEOs of In Silico.

Here are the details of In Silico's key team members:

Alex Zhavoronkov: Co-Founder & Co-CEO of In Silico. They are also an angel investor in 1 startup.
Contact Info: 1 email address
Stephanie Williams: Co-Founder of In Silico.
Contact Info: 1 email address
Feng Ren: Co-CEO of In Silico.
Contact Info: 1 email address

View details of In Silico's Founder profiles and Board Members

In Silico's employee count trend

In Silico has 284 employees as of Jun 26. Here is In Silico's employee count trend over the years:

Uncover In Silico's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of In Silico include Schrodinger, Recursion Pharmaceuticals and XtalPi. Here is the list of Top 10 competitors of In Silico, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Schrodinger 1990, New York City (United States), Acquired	Provider of a web-based simulation and modelling tool	$162M	Gates, WuXi AppTec & 16 others	74/100
2nd	Recursion Pharmaceuticals 2013, New York (United States), Public	AI-enabled drug discovery and development platform for novel therapeutics	$452M	Baillie Gifford, DCVC & 47 others	72/100
3rd	XtalPi 2014, Cambridge (United States), Public	AI-based drug research and development company	$785M	Orbimed, SoftBank Vision Fund & 25 others	67/100
4th	Isomorphic Labs 2021, London (United Kingdom), Series B	Digital platform focused on revolutionizing drug discovery using AI	$2.7B	Thrive Capital, CapitalG & 6 others	64/100
5th	Xaira 2023, San Francisco (United States), Series D	AI-enabled platform for drug discovery and development	$1B	Arch Venture Partners, Foresite Labs & 11 others	63/100
6th	Valo Health 2019, Boston (United States), Series B	AI-powered platform for drug discovery and development	$450M	PSP Investments, Koch Disruptive Technologies ... & 7 others	63/100
7th	Tandem AI 2021, New York (United States), Series A	AI-based drug discovery tool for researchers	$82M	Orbimed, Chengwei Capital & 4 others	62/100
8th	In Silico 2014, Cambridge (United States), Public	AI-enabled bioinformatics platform for drug discovery and biomarker development	$510M	BHR, F-Prime Capital & 36 others	62/100
9th	Causaly 2018, London (United Kingdom), Series B	Provider of an AI platform for life sciences and biomedical research	$93M	EBRD, Iconiq Capital & 14 others	62/100
10th	Healx 2014, Cambridge (United Kingdom), Series C	Provider of AI-powered drug discovery solutions for rare diseases	$115M	Atomico, Amadeus Capital & 19 others	62/100